Maia Anderson Maia Anderson is a senior reporter at Healthcare Brew, where she focuses on pharma developments like GLP-1s and psychedelic medicine, pharmacies, and women's health.
Using weighted trade values from 20202024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth
The FDA established enforcement discretion periods, giving 503A pharmacies until April 2025 and 503B outsourcing facilities until May 2025 to wind down compounded semaglutide production
For researchers evaluating the full landscape of weight loss peptides, SeekPeptides provides continuously updated comparison guides, clinical trial summaries, and community experiences that help navigate this rapidly changing field
What can I expect during a semaglutide treatment